Heart Failure
Three minutes per day doing moderate-intensity domestic tasks may improve heart health
Three minutes of moderate-intensity, unstructured physical activity per day could be enough to reduce risk for major cardiac events and death, researchers reported.
VIDEO: Concomitant tafamidis, acoramidis use does not alter any ATTRibute-CM endpoints
Results of prespecified analyses, presented at the American College of Cardiology Scientific Session, found that tafamidis use in conjunction with acoramidis use did not alter the primary efficacy endpoints of the ATTRibute-CM study.
Finerenone reduces AF risk in patients with heart failure, diabetes, kidney disease
CHICAGO — Finerenone prevented new-onset atrial fibrillation or flutter in patients with chronic kidney disease and type 2 diabetes or heart failure with mildly reduced or preserved ejection fraction, according to new data from FINE-HEART.
TAVR to treat symptomatic aortic regurgitation feasible
CHICAGO — For patients with symptomatic aortic regurgitation at high surgical risk, a transcatheter aortic valve replacement system exceeded safety and performance goals, according to results of the ALIGN-AR trial.
VIDEO: Few women receive counseling, birth control before, after LVAD or heart transplant
In this video, two physicians discuss a study that evaluated the rates of contraceptive prescriptions and counseling in reproductive-aged women before and after left ventricular assist device implant or heart transplant.
VIDEO: ‘Explosion’ of incretin therapy use among new developments in cardiology
NEW ORLEANS — In this video, Clyde W. Yancy, MD, MSc, MACP, MACC, FAHA, FHFSA, discusses notable updates across several areas of cardiology he presented at the ACP Internal Medicine Meeting.
IV iron does not reduce time to hospitalization, death for adults with HF, iron deficiency
CHICAGO — Ferric carboxymaltose, an IV iron replacement therapy, did not reduce the time to first HF hospitalization or CV death for patients with HF and iron deficiency, according to results of a late-breaking clinical trial.
Low life-space mobility raises death, hospitalization risk for older patients with HFpEF
CHICAGO — Older adults with HF with preserved ejection fraction and low vs. high life-space mobility had double the risk for all-cause mortality and hospitalization with a higher likelihood of multimorbidity, researchers reported.
Vutrisiran improves cardiac amyloidosis endpoints regardless of disease severity
CHICAGO — Vutrisiran improved mortality and recurrent CV risks independent of disease severity and improved several other endpoints for a broad spectrum of patients with transthyretin amyloidosis with cardiomyopathy, subgroup analyses show.
Dapagliflozin benefits older patients with heart failure undergoing valve replacement
CHICAGO — The first trial to evaluate use of an SGLT2 inhibitor in people undergoing transcatheter aortic valve replacement showed benefit with dapagliflozin compared with standard care alone, including in older patients.